健脾平肝化浊方干预高血压早期肾损害的临床研究
Clinical Study on the Intervention of Jianpi Pinggan Huazhuo Prescription on Early Renal Damage of Hypertension
DOI: 10.12677/jcpm.2024.34192, PDF,    科研立项经费支持
作者: 董振华, 徐舒雨, 尤清文, 张书研, 程 芳*：浦东新区金杨社区卫生服务中心中医科，上海
关键词: 高血压；早期肾损伤；健脾平肝化浊方；Hypertension； Early Renal Injury； Jianpi Pinggan Huazhuo Prescription
摘要: 目的：观察健脾平肝化浊方治疗高血压早期肾损伤的临床疗效。方法：纳入上海市浦东新区金杨社区卫生服务中心中医科门诊及病房的高血压伴早期肾损伤的患者90例，随机分为中药干预组和对照组，对照组给予西医常规治疗，中药干预组在对照组基础上给予健脾平肝化浊方进行干预。疗程为3个月，观察两组治疗前后血压变化，早期肾损伤指标胱抑素C、β2-MG、NAG、尿mALB变化情况。结果：治疗3个月后，中药干预组收缩压(134.12 ± 4.62) mmHg低于对照组(137.10 ± 3.64) mmHg (t = −3.232, P = 0.002)；舒张压(78.43 ± 4.59) mmHg也较对照组(81.86 ± 5.96) mmHg降低(t = 2.908, P = 0.005)；两组降压疗效比较，中药干预组总有效率为80.95%明显高于对照组的55.0% (χ2 = 6.647, P = 0.036)两组β2-MG水平较治疗前下降，但无明显统计学差异。中药干预组尿mALB水平(69.56 ± 6.45) mg/L较对照组(73.42 ± 7.34) mg/L显著下降(t = −2.295, P = 0.024)。结论：健脾平肝化浊方可协同降低血压，改善高血压早期肾损害指标，一定程度上可逆转靶器官损害。
Abstract: Objective: This paper aims to observe the clinical effect of Jianpi Pinggan Huazhuo prescription on early renal injury of hypertension. Methods: 90 patients with hypertension and early renal injury were enrolled in the outpatient department and ward of Jinyang Community Health Service Center of Pudong New Area, Shanghai. These people were divided into two groups—Chinese herbs intervention group and control group by random number table method. The control group was given conventional Western medicine treatment, and the Chinese herbs intervention was given oral Jianpi Pinggan Huazhuo prescription on the basis of the control group. The treatment course was 3 months. The changes of blood pressure, cystatin C, β2-MG, NAG and urinary mALB of the two groups were compared. Results: After 3 months of treatment, the systolic blood pressure (134.12 ± 4.62) mmHg in the intervention group was lower than that in the control group (137.10 ± 3.64) mmHg (t = −3.232, P = 0.002). The diastolic blood pressure (78.43 ± 4.59) mmHg was lower than that of the control group (81.86 ± 5.96) mmHg (t = 2.908, P = 0.005). The total effective rate of 80.95% in the intervention group was significantly higher than 55.0% in the control group (χ2 = 6.647, P = 0.036); The levels of β2-MG in the two groups were lower than before treatment, but there was no significant difference. Urinary mALB level in the intervention group (69.56 ± 6.45) mg/L was significantly lower than that in the control group (73.42 ± 7.34) mg/L (t = −2.295, P = 0.024). Conclusion: Jianpi Pinggan Huazhuo turbidity can synergistically reduce blood pressure, improve early renal damage index of hypertension, and reverse target organ damage to a certain extent.
文章引用：董振华, 徐舒雨, 尤清文, 张书研, 程芳. 健脾平肝化浊方干预高血压早期肾损害的临床研究[J]. 临床个性化医学, 2024, 3(4): 1357-1363. https://doi.org/10.12677/jcpm.2024.34192

参考文献

[1] 叶尔克江∙尼加提, 马丽. 中医药防治高血压病早期肾损害的研究进展[J]. 新疆中医药, 2018, 36(1): 94-96.
[2] Wang, J., Zhang, L., Wang, F., Liu, L. and Wang, H. (2014) Prevalence, Awareness, Treatment, and Control of Hypertension in China: Results from a National Survey. American Journal of Hypertension, 27, 1355-1361. [Google Scholar] [CrossRef] [PubMed]
[3] 胡盛寿, 高润霖, 刘力生, 等. 《中国心血管病报告2018》概要[J]. 中国循环杂志, 2019, 34(3): 209-220.
[4] Wang, Z., Chen, Z., Zhang, L., Wang, X., Hao, G., Zhang, Z., et al. (2018) Status of Hypertension in China: Results from the China Hypertension Survey, 2012-2015. Circulation, 137, 2344-2356. [Google Scholar] [CrossRef] [PubMed]
[5] Batchu, S.N., Dugbartey, G.J., Wadosky, K.M., Mickelsen, D.M., Ko, K.A., Wood, R.W., et al. (2018) Innate Immune Cells Are Regulated by Axl in Hypertensive Kidney. The American Journal of Pathology, 188, 1794-1806. [Google Scholar] [CrossRef] [PubMed]
[6] 杨维中. 建强初级卫生保健体系是实现健康中国的重要保障[J]. 中国初级卫生保健, 2023, 37(5): 1-4.
[7] 中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会中国医师协会高血压专业委员会, 中国医疗保健国际交流促进会高血压分会, 等. 中国高血压防治指南(2018年修订版) [J]. 中国心血管杂志, 2019, 24(1): 24-56.
[8] 郑筱萸. 中药新药临床研究指导原则(试行) [M]. 北京: 中国医药科技出版社, 2002: 156-162, 233-237.
[9] 韩学杰. 高血压病中医诊疗方案(初稿) [J]. 中华中医药杂志, 2008, 23(7): 611-613.
[10] 董振华. 活血潜阳祛痰方对肥胖高血压心肌肥厚的临床疗效及基于SIRT1/PGC-1α通路的机制探讨[D]: [博士学位论文]. 上海: 上海中医药大学, 2019.
[11] 王庆芳, 张强, 蔡安萍, 等. 高血压慢性肾脏病患者的流行病学研究[J]. 医药论坛杂志, 2008, 29(10): 8-10.
[12] 黄俊, 王永红, 马华兰. 血清胱抑素C、β2微球蛋白、尿微量白蛋白联合检测在糖尿病肾病早期诊断中的临床价值[J]. 中国卫生检验杂志, 2017, 27(1): 54-56.
[13] 周连华, 范玉娟, 姜文娟, 等. 血清胱抑素C在早期糖尿病肾病患者肾功能受损评价中的诊断价值[J]. 临床内科杂志, 2012, 29(2): 108-109.
[14] 王茵, 闫国贝, 刘芳松. 中医血α1、β2微球蛋白和胱抑素C及尿微量蛋白对高血压早期肾损害的诊断价值[J]. 中国卫生工程学, 2023, 22(2): 195-197.
[15] Xu, F.Q., Yang, Y.Q. and Liu, J. (2013) Research Progress in Detection of Serum Cystatin C and Its Clinical Application. Medical Recapitulate, No. 16, 2907.
[16] 马红霞, 周运恒, 杨蔺, 等. 胱抑素C的临床价值研究进展[J]. 国际检验医学杂志, 2009, 30(10): 974-975.
[17] 焦鑫, 何思春, 邹立新. 尿微量蛋白和血β2微球蛋白测定在高血压患者早期肾损害中的意义[J]. 四川医学, 2008, 29(10): 1415-1416.
[18] Bhavsar, N.A., Appel, L.J., Kusek, J.W., Contreras, G., Bakris, G., Coresh, J., et al. (2011) Comparison of Measured GFR, Serum Creatinine, Cystatin C, and Beta-Trace Protein to Predict ESRD in African Americans with Hypertensive CKD. American Journal of Kidney Diseases, 58, 886-893. [Google Scholar] [CrossRef] [PubMed]
[19] 赵晓静, 韩书光, 李贝贝, 等. 血浆NGAL、尿NAG及尿RBP在诊断早期糖尿病肾脏疾病中的价值[J]. 检验医学与临床, 2024, 21(1): 57-64.
[20] 任艳丽, 吴铁, 李晓媛, 等. 尿微量白蛋白检测在糖尿病肾病早期诊断中的价值[J]. 中国地方病防治杂志, 2012, 27(6): 480.
[21] 刘玉宁, 王耀献. 高血压肾损害病理变化的中医病机探讨[J]. 中国中西医结合肾病杂志, 2012, 13(1): 1-3.
[22] 秦建国, 郭一, 韩琳, 等. 从“肾络瘀损”探讨高血压肾损害的中医病机与治疗[J]. 中国中西医结合肾病杂志, 2015, 16(9): 834-835.
[23] 王宪赟, 李振华, 王怡. 温肾化痰方治疗早中期高血压病肾脏损害临床研究[J]. 中医学报, 2017, 32(224): 131-134.
[24] 王鹏, 裴朝华, 方芳, 等. 益气化瘀、平肝滋肾方治疗高血压肾损害的临床观察[J]. 中西医结合心脑血管病杂志, 2023, 21(15): 2822-2826.
[25] 周志, 班秀芬, 王秀仪, 等. 活血通脉颗粒对高血压中期肾损害患者血肾功能及中医证候积分的影响[J]. 中国民族医药杂志, 2023, 29(7): 34-35.
[26] 陈兴娟, 杨传华. 补肾和脉降浊法治疗老年高血压肾损害经验总结[J]. 长春中医药大学学报, 2012, 28(1): 77-78.